- Stocks
- Pharma & Healthcare
- Hemant Surgical
Hemant Surgical share price
NSE: HSILPharma & HealthcareMedical Devices
Hemant Surgical at a glance
With a market capitalisation of ₹551 Cr, it ranks 1762nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.
Its return on equity was 13.9% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹785 Cr (+14.2% year on year) and net profit ₹99 Cr (+11.8%), on a consolidated basis. Promoters held 52.83% of the company as of 18 May 2026.
Key numbers
- Market cap
- ₹551 CrRank 1762 on NSE
- Price to book
- 2.06×FY26
- EPS (TTM)
- ₹55.98to Q1 FY27
- ROE
- 13.9%FY26
- ROCE
- 19.5%FY26
- Debt to equity
- 0.36FY26
- Net profit margin
- 8.3%FY26
- Book value / share
- ₹105.57FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Hemant Surgical quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹599 Cr | ₹658 Cr | ₹705 Cr | ₹688 Cr | ₹602 Cr | ₹634 Cr | ₹742 Cr | ₹785 Cr |
| Revenue YoY | — | — | — | +21.4% | +0.4% | −3.8% | +5.3% | +14.2% |
| Net profit | ₹72 Cr | ₹91 Cr | ₹97 Cr | ₹89 Cr | ₹76 Cr | ₹71 Cr | ₹115 Cr | ₹99 Cr |
| Net profit YoY | — | — | — | +40.5% | +5.4% | −21.1% | +19.4% | +11.8% |
| Net margin | 12.0% | 13.7% | 13.7% | 12.9% | 12.6% | 11.3% | 15.5% | 12.7% |
| EPS | ₹11.14 | ₹13.99 | ₹14.93 | ₹13.73 | ₹11.75 | ₹11.04 | ₹17.83 | ₹15.36 |
Hemant Surgical financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹106 Cr | ₹107 Cr | — |
| Operating profit | ₹13 Cr | ₹11 Cr | — |
| Net profit | ₹10 Cr | ₹8 Cr | — |
| EPS (₹) | ₹9.85 | ₹7.79 | — |
| Cash from operations | −₹8 Cr | ₹9 Cr | — |
| Total debt | — | ₹23 Cr | ₹3 Cr |
| Shareholders' equity | — | ₹63 Cr | ₹138 Cr |
Hemant Surgical shareholding pattern
| Holder | 30 Sep 2024 | 31 Mar 2025 | 19 Sep 2025 | 30 Sep 2025 | 31 Mar 2026 | 18 May 2026 |
|---|---|---|---|---|---|---|
| Promoters | 73.56% | 73.56% | 58.90% | 58.90% | 58.90% | 52.83% |
| Foreign institutions | — | 0.39% | 0.15% | 0.15% | 0.15% | 0.14% |
| Domestic institutions | 1.13% | 1.11% | 10.81% | 10.81% | 10.73% | 19.94% |
| Non-institutions | 25.30% | 24.93% | 30.14% | 30.14% | 30.21% | 27.10% |
Hemant Surgical vs peers
The listed Pharma & Healthcare companies nearest to Hemant Surgical by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| WANBURYWanbury | ₹187.00 | −3.36% | −25.8% | ₹653 Cr | 9.6 | — |
| HSILHemant Surgical | — | — | — | ₹551 Cr | — | — |
| PREVESTPrevest Denpro | — | — | — | ₹472 Cr | — | — |
| HALEOSLABSHALEOS LABS | ₹1,540.00 | +0.59% | +36.5% | ₹466 Cr | 26.9 | — |
| ALBERTDAVDAlbert David | ₹795.00 | −3.90% | −0.6% | ₹454 Cr | — | — |
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
Ask anything about Hemant Surgical
Pivot answers on the live chart with evidence you can check, and tests strategies against HSIL's own history. Try: “Why has HSIL moved over the last three months?” · “Backtest a 50-day moving-average crossover on HSIL over five years” · “Compare HSIL with AMANTA on margins and valuation”
Frequently asked questions about Hemant Surgical
What is the market cap of Hemant Surgical?
Hemant Surgical's market capitalisation is ₹551 Cr (₹551 Cr) at the 19 Oct 2026 close, ranking 1762nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Hemant Surgical?
Return on equity was 13.9% in FY26 and return on capital employed was 19.5% in FY26 (consolidated figures).
Is Hemant Surgical a debt-free company?
No. Hemant Surgical's debt-to-equity ratio was 0.36 in FY26, with total debt of ₹3 Cr.
What were Hemant Surgical's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Hemant Surgical reported revenue of ₹785 Cr, +14.2% year on year, and net profit of ₹99 Cr, +11.8% year on year.
What is the shareholding pattern of Hemant Surgical?
As of 18 May 2026: promoters 52.83%, foreign institutions 0.14%, domestic institutions 19.94%, non-institutions 27.10%.
Who are Hemant Surgical's competitors?
The listed Pharma & Healthcare companies closest to Hemant Surgical by market cap are Amanta Healthcare, Wanbury, Prevest Denpro, HALEOS LABS, Albert David and Asarfi Hospital.
Is Hemant Surgical a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Hemant Surgical's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HSIL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text